Eagle, my interpretation of that comment was Jon referring to the vastly improved economics achievable when licensing an asset with FDA marketing approval, vs a post ph2 asset.
Recall that the deal done with Acadia in August 2018 included a USD $10m upfront payment. A laughable amount in the context of a drug with marketing approval.
Having said that, I'm all for a buyout at the right time and the right price. I've been here since 2013 so I'm patient!
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$14.20 |
Change
0.890(6.69%) |
Mkt cap ! $1.761B | |||
| Open | High | Low | Value | Volume |
| $13.50 | $14.26 | $12.96 | $9.111M | 655.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2000 | $14.17 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.23 | 3278 | 1 |
View Market Depth
| Last trade - 16.15pm 27/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |